Cargando…
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
During the past decade, progress has been made in the field of lung cancer molecular biology and onco-immunology, leading to prolonged survival of patients. The combination of increased fundamental knowledge and the pharmaceutical pipeline has allowed the development of various tyrosine kinase inhib...
Autores principales: | Mogenet, Alice, Greillier, Laurent, Tomasini, Pascale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374839/ https://www.ncbi.nlm.nih.gov/pubmed/34429632 http://dx.doi.org/10.2147/PGPM.S267437 |
Ejemplares similares
-
Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017) -
Bevacizumab in the treatment of nonsquamous non-small cell lung
cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016) -
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
por: Marolleau, Sophie, et al.
Publicado: (2023) -
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019) -
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)